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Electroporation (EP) is a method used to physically deliver therapeutic molecules such as
plasmid DNA directly to tissues. It has been used safely and successfully in clinical studies
and preclinical cancer models to deliver genes to a variety of tissues. In cancer research
cytokine therapy is emerging as a promising tool that can be used to boost the host response
to tumor antigens. The delivery of cytokines as recombinant proteins can result in toxicity and
other adverse effects; however the delivery of cytokine genes using EP has been shown to
be safe and effective. Interleukin 15 (IL-15) is a cytokine that promotes the innate as well
as the adaptive immune response to cancer cells and bacterial pathogens. In this study we
used EP to deliver a human IL-15 plasmid (phIL-15) directly to tumors to examine its anticancer effects. B16.F10 melanoma tumors were induced in C57BL/6J mice and phIL-15 was
delivered three times over the course of a week. Expression of the transgene, tumor volume,
long-term survival and resistance to challenge were monitored in these animals. Delivery of
IL-15 plasmid by EP resulted in increased IL-15 expression within the tumor compared to
the injection only control. This expression peaked at 12 to 18 hours after the first delivery
and was sustained at lower levels after the second and third deliveries. The delivery of
the phIL-15 resulted in tumor regression, long-term survival and greater protection against
tumor recurrence when cancer cells were reintroduced compared to control plasmid. From
these results we can conclude that the delivery of IL-15 plasmid to tumors using EP is a
promising avenue to investigate for its anti-tumor effects, however more work needs to be
done to increase the stability of the gene once it is delivered and to elucidate the anti-tumor
mechanism.
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Introduction
Electroporation (EP) is a physical method for delivering molecules such as DNA
into cells. It utilizes electric fields to alter the permeability of the cell membrane in order to allow molecules to enter the cell (1). Many studies evaluate
the effectiveness of using EP to deliver therapeutic genes to a variety of tumor
types to control tumor burden by inducing proteins that through downstream
signaling cause anti-tumor effects (2-5). The advantage to using this approach
is delivering therapeutic molecules directly to the tumor site without affecting
the surrounding normal tissue and generating unwanted side effects. The transfection efficiency of gene electrotransfer can be modulated by changing the EP
parameters used such as the voltage, duration and the number of pulses (6, 7).
Abbreviations: EP: Electroporation; phIL-15: Human Interleukin 15 Plasmid.
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EP for gene delivery has been extensively studied in a number of preclinical melanoma models (8) which lead to the
first-in-man clinical trial that utilized EP to deliver interleukin-12 (IL-12) directly to tumors (9). Studies have also
shown that delivery of non-coding plasmid DNA using EP
can stimulate inflammatory as well as anti-tumor responses
(10, 11) and EP can recruit immune cells to the site of administration (12). This provides an added advantage when using
this delivery method for cancer therapy.
Interleukin 15 (IL-15) is a 15 kDa cytokine that binds to
IL-15 alpha receptor (IL-15Rα) chain and signals through the
gamma and beta chains of the IL-2 receptor complex (13, 14).
It is closely related to IL-2 and since it shares the same receptor, there is some overlap of their functions. In vivo IL-15 has
been shown to regulate the homeostasis of both innate and
adaptive immune cells (15). It induces the proliferation of B
cells, the activation and proliferation of CD41 and CD81
lymphocytes, promotes the induction of cytolytic effector
cells, maintains survival of memory CD81 T cells, and acts
as a potent T cell chemoattractant (16). It also stimulates the
proliferation and activation of NK cells and acts as a costimulator with IL-12 to produce interferon gamma and tumor
necrosis factor (17-19). IL-15 has a high affinity for binding
its IL-15Rα (20). This complex can then stimulate neighboring cells through transpresentation which is essential for
mediating the biological effects of IL-15 (21). The innate
immune system plays a crucial role in host defense against
tumor cells and pathogens. IL-15 is an attractive anti-cancer
therapeutic target because of its ability to not only stimulate
the adaptive immune system but the innate immune system
as well (22, 23).
Melanoma is an aggressive cancer that evades the host immune
system by increasing the production of immunosuppressive
genes, reducing antigen presentation and preventing the induction of effector cells (24). Within the tumor, there are alterations in cell-cell communication and adhesion which leads to
disease progression (25). The increased expression of a therapeutic molecule such as IL-15 in combination with the inflammatory responses generated by electrically mediated transfer of
plasmid DNA may allow for an increased presence of immune
effector cells within the tumor and promote tumor regression.
Specifically it would enhance non-specific killing of tumor
cells by the innate immune system, enhance presentation of
tumor antigens, recruit cells of the adaptive immune system
and generate long-term memory against recurring tumor cells.
Intratumoral electrotransfer of various cytokines such
as IL-21, and IFN-γ in experimental cancer models have
resulted in long-term tumor regression (26-28). Delivery of
IL-12 with EP to melanoma resulted in local and systemic
expression of the gene, tumor regression, long-term survival
and resistance to challenge (9, 29, 30). Delivery of IL-15
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using EP to melanoma in vivo resulted in tumor regression,
long-term survival and protection from re-introduced cancer
cells (31). Previous studies in the mouse model have shown
that a single delivery of IL-12 with EP was not sufficient to
cause tumor regression, although two treatments were able to
induce regression in 47% of the animals (30, 32). Similarly,
two deliveries of IL-15 with EP were only able to induce
tumor regression in 40% of the animals. Here we examine
the therapeutic potential of three deliveries of IL-15 using
EP. It is hypothesized that increasing the number of treatments will increase the rate of survival.
Materials and Methods
Tumor Cells
B16.F10 mouse melanoma cells (ATCC, Manassas, VA)
were maintained in McCoy’s medium supplemented with
10% FBS and 1% gentamycin at 378C and 5% CO2 humidified air. Cells were removed from flasks using trypsin without
EDTA (Atlanta Biologicals, Lawrenceville, GA) and washed
in sterile DPBS without calcium and magnesium (Mediatech,
Cellgro, Manassas, VA). Cell viability was assessed by trypan blue exclusion dye method. Cells with a viability .90%
were resuspended in sterile DPBS at a concentration of
2 3 107 per ml for injection.
Tumor Induction
Tumors were established in the shaved left flank of female
6-8 week-old C57BL/6J mice (Jackson Labs, Bar Harbor,
ME) by subcutaneous injection of 0.05 ml (1 3 106) B16.F10
melanoma cells. Tumors were allowed to grow for 6-10 days
to a volume of 30-60 mm3 before treatment. For challenge
studies, tumors were established on the right flank by subcutaneous injection of 0.05 ml (5 3 105) B16.F10 melanoma
cells.
Plasmids
phIL-15 was a generous gift from Dr. David B. Weiner
(University of Pennsylvania, College of Medicine). The plasmid contains an optimized IL-15 sequence that was cloned
into a pVAX1 cloning vector (Invitrogen, Carlsbad, CA) (33,
34). phIL-15 and control vector pVAX1 were commercially
prepared to endotoxin levels of ,100 EU/mg (Aldevron,
Fargo, ND) and diluted in 0.9% sterile injectable saline to the
appropriate concentration for each experiment.
Plasmid Delivery by Electroporation
Plasmid was delivered directly to tumors on days 0, 3,
and 6 after the tumors grew to the appropriate volume
(30-60 mm3). The number of times the plasmid was delivered
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to a given tumor varied depending on the experimental
group. Mice were anesthetized by placing animals into an
induction chamber infused with a mixture of 3% isoflurane
and 97% oxygen for several minutes. They were then fitted
with a standard rodent mask and exposed to 2-3% isoflurane in oxygen during all treatments. Mice received 50 µl
of plasmid (1.0 mg/ml or 2.0 mg/ml of phIL-15 or pVAX1)
by intratumoral injection. An applicator containing 6-needle
penetrating electrodes in a circular array was placed around
the tumor and pulses were applied using the ECM 830 Square
Wave Pulse generator (BTX Harvard Apparatus, Holliston,
MA). Mice were divided into three electroporation groups:
one group received 6 pulses of field strength 1300 V/cm
(voltage across distance (0.92 cm)) and pulse length 100 µs,
the second group received 6 pulses of field strength 500 V/cm
and pulse length 20 ms, and the third group received 6 pulses
of field strength 200 V/cm and pulse length of 20 ms. Control
groups received intratumoral injections of hIL-15 expressing
plasmid only. Experimental groups used to monitor long-term
survival had a starting n of 15. Some animals had tumors that
were deep and embedded in the underlying muscle tissue or
had developed a second tumor near the site of the primary
tumor. These animals were dropped from the study.
Tumor Measurements
Tumors were measured every 3 to 4 days using a digital caliper. Tumor volume was determined using the standard formula V 5 pab2/6, where (a) is the longest diameter and (b) is
the shortest diameter perpendicular to (a) (35). The mice were
monitored for tumor growth for the duration of the experiment
or until tumor volumes reached 1000 mm3, at which point the
animals were humanely euthanized with CO2.
ELISA
Tumors were collected from humanely euthanized mice,
frozen immediately on dry ice and stored at 2808C. Blood,
was collected from mice under mild anesthesia via retroorbital bleeding into serum separator tubes (BD). Serum
was collected after centrifugation (5 minutes at 1000 rpm)
at 48C and stored at 2208C until analyzed. To measure cytokine levels within the tumor tissue, samples were thawed,
weighed, and diluted in 500 µl-800 µl of PBS with protease
inhibitor cocktail (Roche, Brandford, CT) dependent on
sample size. Tissue samples were kept on ice and homogenized using a PowerGen 700 (Fisher Scientific, Pittsburg,
PA). The homogenate was centrifuged at 1000 rpm for 5
minutes at 48C. Expression levels of IL-15 were measured
using a human IL-15 Quantikine ELISA kit (R&D Systems,
Minneapolis, MN) per the manufacturer’s instructions.
hIL-15 levels were calculated as pg/ml of tumor homogenate and normalized to tumor weight. The data is expressed
as pg/0.1 g of tumor.
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Statistical Analysis
The results were analyzed using Microsoft Excel and
Statistical Package for the Social Sciences (SPSS-IBM,
Chicago, IL) software to determine significance. A two-tailed
Student’s t-test was utilized for the analysis of hIL-15 in the
tumor lysate from treated groups compared to the injection
only control at each time point. The Three Sigma Rule and
Z score were used to identify and remove outliers greater
than 2.5 standard deviations during analysis of significance.
Differences were deemed significant when a p value was
,0.05. At least three independent experiments were performed for these experiments.
Results and Discussion
Intratumoral Delivery of phIL-15 Using EP Results in IL-15
Expression
In order to determine the usefulness of delivering IL-15 using
EP as an in vivo treatment for melanoma we first tested the
expression of IL-15 in the tumor after delivery of phIL-15.
Previous studies have characterized the expression kinetics
and therapeutic effects of multiple intratumoral deliveries of
pDNA using EP (30-32). Studies have shown, using various
tumor models and various methods of delivering the plasmids, that local expression of immune modulators is important for successful tumor regression (36-39). 50 µl of plasmid
DNA was injected into the tumor and a train of six pulses
of various electric field strengths and pulse lengths were
applied to the tumor using an applicator with six penetrating
electrodes in a circular array. These pulse protocols include
1300 V/cm 100 µs pulses, 500 V/cm 20 ms pulses or 200 V/cm
20 ms pulses. Two concentrations of plasmid were tested,
1 mg/ml and 2 mg/ml and the level of expression in the tumor
was determined. Tumor tissue was collected at 12, 18, 24 and
48 hours after a single delivery, 12 hours after two deliveries
on days 0 and 3, and 12 hours after three deliveries on days
0, 3, and 6. The tissue was homogenized in PBS and analyzed
by hIL-15 ELISA. The data are reported as pg/0.1 g of tumor
over time as shown in Figure 1. IL-15 expression levels were
also measured in serum (data not shown) and found to be less
than 3 pg/ml for all groups.
Statistically significant, early, short-term increases in the levels
of IL-15 protein were observed when phIL-15 was delivered
using 1300 V/cm, 100 µs pulses and 500 V/cm, 20 ms pulses
compared to injection alone. The expression levels of IL-15
decreased steadily among all groups over the 48 hours period.
When phIL-15 was delivered using 200 V/cm 20 ms pulses,
expression appeared later and the levels were lower than that
of the other pulse protocols. These values were not statistically
significant. Expression was not measured in tumors using the
200 V/cm 20 ms EP protocol to deliver phIL-15 (2 mg/ml)
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48 hours. Mice with tumors that received 2 mg/ml of phIL-15
and EP at this protocol showed a 10.5 and 28 fold increase
over the injection only control (p  0.001) at 12 and 18 hours
after delivery respectively and maintained an elevated level of
expression from 24 to 48 hours. When phIL-15 was delivered
to tumors using 1300 V/cm 100 µs pulses as a single delivery
the IL-15 expression was lower that of the groups that received
500 V/cm 20 ms pulses at 12, 18, and 48 hours but comparable
at 24 hours. When phIL-15 (1 mg/ml) was delivered to tumors
using 1300 V/cm 100 µs pulses expression appeared to peak
after 24 hours and showed a 15.1 fold increase over the injection only control (p , 0.0001). When phIL-15 (2 mg/ml) was
delivered by EP using this protocol, IL-15 expression peaked
at 12 hours after the single delivery and remained through
24 hours before falling off at 48 hours.
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further investigated the effects on IL-15 expression after three
deliveries of pIL-15 using EP on days 0, 3, and 6 (Figure 2).
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Figure 1: Analysis of tumor homogenate for hIL-15 expression after a
single delivery of phIL-15. Expression of hIL-15 was measured by ELISA at
12, 18, 24, and 48 hours after a single intratumoral delivery of 50 µl
of phIL-15 at a concentration of 1.0 mg/ml (A) or at a concentration of
2.0 mg/ml (B) using electroporation with various parameters delivered by a
circular 6 penetrating electrode array. Data is represented as the mean
hIL-15 concentration (pg/0.1g of tumor). Error bars represent standard
deviation. Student t-test was performed to calculate significance for each
group compared to injection only at that time point. The number of animals
in each group tested were between 8 and 16. P pulses; *p value , 0.05. No
samples were tested at 24 and 48 hours for mice that received phIL-15 with
six 20 ms pulses at 200 V/cm.
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at 24 and 48 hours. The highest IL-15 expression levels were
detected at 12 and 18 hours after a single delivery in all samples that were treated with 500 V/cm 20 ms pulses. Mouse
tumors that received 1 mg/ml of phIL-15 and EP using this
protocol showed a 17.6 and 26.4 fold increase over injection
only control (p  0.001) at 12 and 18 hours after delivery
respectively. Expression decreased thereafter but remained
significantly higher than the injection only control through

Figure 2: Analysis of tumor homogenate for hIL-15 expression after a
multiple deliveries of phIL-15. Expression of phIL-15 was measured by
ELISA 12 hours after two intratumoral deliveries of 50 µl of phIL-15
(2.0 mg/ml) on days 0 and 3 and 12 hours after three deliveries of 50 µl of
phIL-15 (2.0 mg/ml) on days 0, 3, and 6 using electroporation with various
parameters delivered by a circular 6 penetrating electrode array. Data is presented as the mean hIL-15 concentration (pg/0.1 g of tumor) over time. Error
bars represent standard deviation. Student t-test was performed on each
sample and significance calculated based on the injection only group at each
time point. n 5 12 for each group tested. P pulses; *p value , 0.05.
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were collected after the day 3 and 6 deliveries, both EP conditions used showed significantly elevated IL-15 expression
in the tumor compared to the injection only control. These
levels were not higher than the levels detected 48 hours after
a single delivery. From these results it does not appear that
multiple deliveries of plasmid using EP elevates IL-15 levels
in the tumors to those seen 12 hours after a single delivery.
However, it is clear that multiple deliveries can effectively
sustain IL-15 expression at statistically significant levels
above injection only control in tumors for more than six days.
This indicates that the animals are either building a resistance to the foreign human protein or that the human IL-15
is unstable and is being regulated in some other way after it
is secreted. Studies have shown that the IL-15Rα is important in stabilizing IL-15 in vivo and preventing degradation
through the proteasome (40). Other studies show that formation of a complex between the IL-15 and the IL-15Rα is
essential for trans-presentation and subsequent signaling on
neighboring cells (41). Since the experiments in this report
did not include co-delivery of an IL-15Rα plasmid this could
be a contributing factor to the low levels of IL-15 seen in the
tumor after plasmid delivery with EP and the low levels seen
in the serum at corresponding time points (data not shown).
IL-15 is a tightly regulated cytokine and its expression is controlled at the levels of transcription, translation and intracellular trafficking (42). The plasmid used in this study encodes
human IL-15 and was optimized in an attempt to overcome
these impediments and produces a biologically active protein
that expresses 80-fold higher than the native construct (33).
Human IL-15 shares a 73% homology with the mouse gene. It
enhances antigen specific CD81 immune responses and elicits an anti-tumor response when delivered by EP to melanoma

Control
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(31, 33). Human IL-15 binds to mouse IL-15Rα with a similar affinity as the mouse IL-15 but the specific activity of the
human protein expressed in the mouse is much lower than the
mouse protein (43). The human IL-15 was shown to be less
effective at increasing the number and activity of spleen NK
and CD81 cells in the mouse than the mouse IL-15 protein.
It was also suggested that IL-15 can be physiologically active
in some systems without the involvement of the IL-15Rα.
This provides evidence that the levels of human IL-15 generated in the tumors bind to the endogenous mouse IL-15Rα
and are most likely physiologically active.
Electroporation has been shown to be an effective means of
delivering plasmid DNA to tissues. The selection of electrodes
and pulse parameters such as pulse number, length and amplitude are important to the efficiency of permeabilization of cells
in a given tissue (7, 44). The objective is to achieve tissue permeabilization without causing cell death. It has been reported
that various EP protocols can result in gene transfer (45). Protocols using millisecond pulses at relatively low voltage usually result in higher, prolonged gene expression compared to
high voltage millisecond pulses. In this study we evaluated
three EP conditions: six 200 V/cm, 20 ms pulses; six 500 V/cm,
20 ms pulses; and six 1300 V/cm, 100 µs pulses. All pulses were
delivered using an applicator with a circular array of six penetrating electrodes placed around the tumor. We found that the
200 V/cm, 20 ms EP pulses were not sufficient to generate high
levels of IL-15 after the plasmid was delivered. The most efficient delivery of the plasmid as evidenced by gene expression
was shown by the 500 V/cm, 20 ms pulses followed by the
1300 V/cm, 100 µs pulses. Though the 500 V/cm pulses generate higher gene expression, they generate visible tissue damage
(Figure 3) that resulted in scarring of the skin and tissue.

pVAXl

pVAXl

ph ll-15

phll-15

1300 V/cm, 100 µs ,

500 V/cm, 20 ms,

1300 V/cm, 100 µs,

500 V/cm, 20 ms,

q
.-<

>

ro
0

0

Lil

r;0

Figure 3: Effect of delivery of plasmid by electroporation on animal skin. All animals except controls received three deliveries of plasmid using EP on days
0, 3, and 6. Images were captured on day 14 (A-E) and day 50 (F-J). Images depict untreated (A) and treated tumors (B-E and G-J) and (F) naïve mouse.

Technology in Cancer Research & Treatment, Volume 13, Number 6, December 2014

556

Marrero et al.

Delivery of pIL-15 Using EP Results in Tumor Regression
and Long-term Survival
To determine the potential of delivering phIL-15 to tumors
using EP as an antitumor therapy, we delivered 50 µg of
phIL-15 (2 mg/ml) in sterile saline into established tumors
on C57BL/6J mice followed by EP on days 0, 3, and 6. Previous studies have shown the efficacy of a three treatment
EP mediated delivery of plasmid DNA for tumor regression
(32, 46). An applicator consisting of six penetrating electrodes in a circular array was used to deliver six 1300 V/cm,

100 µs pulses or 500 V/cm, 20 ms pulses to the tumor. The
mice were monitored over the course of 50 days and the
tumor volume recorded (Figure 4). The data are expressed
as the percent of the tumor volume on day zero (% day zero
volume) and reported for non-responders (Figure 4A) as
well as responders (Figure 4B). Percent survival is reported
in Figure 5.
Control mice that received only injection of phIL-15 (no EP)
showed no response to treatment, their tumors increased in
size and the animals were humanely euthanized about two
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Figure 4: Tumor regression after multiple deliveries of phIL-15 using electroporation. Tumor volume (mm3) monitored over 50 days for non-responders (A)
and responders (B) following intratumoral delivery of 50 µl of phIL-15 (2.0 mg/ml) on days 0, 3, and 6 using either six 100 µs pulses at 1300 V/cm or six 20 ms
pulses at 500 V/cm delivered by penetrating electrode array. The group that received phIL-15 using six 20 ms pulses at 500 V/cm had one mouse represented
on the non-responder graph (A), with a tumor that increased in volume up to day 30 and then regressed. On day 51 there was a measureable mass. Data is
represented as the average percentage of the volume of the tumor at day zero. Error bars represent standard deviation. The number of responders or nonresponders is indicated on the graph as a fraction of the total number of animals in each group. P pulses; pVAX1 control plasmid; phIL-15 plasmid encoding
the hIL-15 gene.
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underlying tissues (Figure 3). Pulses delivered at 1300 V/cm
for 100 µs did not cause any visible damage to the skin of
the animals. The interesting finding in this study is the tumor
regression, long-term survival and the generation of a tumorspecific memory response by the mice that received control
plasmid. Studies have shown that EP can act as an adjuvant in
recruiting immune cells to the site of administration (11, 12).
This effect of the EP pulses combined with the tissue damaging nature of the 20 ms pulses at 500 V/cm could lead to an
increased presence of immune cells in the tumor and account
for the increase in tumor regression and long-term survival
seen in mice receiving the control plasmid with EP. The lack
of visible damage to the tissue when 1300 V/cm pulses were
delivered might lead to fewer immune cells recruited to the
tumor, resulting in the lower survival rates observed for mice
receiving the control plasmid. Since the EP adjuvant effect
appears to be muted under these conditions the higher survival rate of mice receiving phIL-15 with EP at 1300 V/cm
could then be attributed to the physiological function of IL-15
in the tumor.

weeks after the last delivery. Plasmid DNA (phIL-15 as well
as control plasmid pVAX1) delivered to tumors using EP
induced tumor regression and long-term survival in a percentage of the animals in each group (Figure 4B). Tumor volume
steadily decreased over the first three weeks and the animals
were all tumor free by day 24. These animals remained tumor
free for the duration of the experiment and were challenged
on day 56. No additional treatments were administered. One
animal in the group that was treated with control plasmid
and 20 ms pulses at 500 V/cm showed a partial response
until day 39, after which the tumor volume began increasing
(Figure 4A). In the group that was treated with phIL-15 using
this pulse protocol, one animal showed a partial response as
well. In this case the tumor volume slowly increased over the
first four weeks, remained constant for a few days and then
decreased thereafter (Figure 4A). Melanoma is an aggressive cancer with metastatic properties so it is important to
note that in some cases cells may have already migrated from
the primary site before the plasmid was delivered and therefore would not be treated. This would result in the animal
being classified as non-responsive to the phIL-15 therapy due
to the growth of a distant untreated tumor.

Plasmid DNA that does not encode a therapeutic gene delivered by EP has anti-tumor effects (11). Heller et al. showed
that the delivery of a plasmid encoding luciferase using ten
5 ms pulses at 800 V/cm with caliper electrodes induced
greater tumor regression and long-term survival than plasmid delivered using 1300 V/cm pulses. Delivery of pUC18,
a plasmid that contains no mammalian sequences, using
5 ms pulses at 800 V/cm resulted in tumor regression and
long-term survival in 70% of the mice. These findings are
similar to what was observed for pVAX1 delivered by EP in
this report where vector control plasmid delivered by 20 ms
pulses at 500 V/cm resulted in greater survival than vector
plasmid delivered by 100 µs pulses at 1300 V/cm. These antitumor effects could be attributed to the CpG motifs that are
present on the plasmid DNA as these sequences can cause
tumor-specific immune responses (47-50). Plasmid delivery
by EP alters endogenous mRNA and protein expression of
cytokines and chemokines in melanoma based on the pulse
parameters used (10). EP itself has also been shown to activate proinflammatory chemokine and stress genes and cause
an influx of inflammatory cells to the site of administration
(51, 52). The generation of these cytokines could play a role
in the tumor-specific responses demonstrated in this report in
groups of mice that received control plasmid with EP.

Mice that received phIL-15 delivered with 1300 V/cm 100 µs
pulses showed 100% survival compared to a 43% survival
for mice given control plasmid using the same EP conditions.
phIL-15 delivered using 500 V/cm 20 ms pulses showed
58% survival compared to a 77% survival for mice given
the control vector (pVAX1). Pulses delivered under this EP
condition using this penetrating electrode array caused visible damage to the skin of the animal and potentially to the

From this study we have shown that three deliveries of
phIL-15 can increase the percentage survival of the animals
treated when compared to a previous study with two administrations of phIL-15 (31). Using three deliveries the group
treated with six 100 µs pulses at 1300 V/cm and showed 100%
survival at day 51, an improvement over the 40% survival
shown by mice that received phIL-15 delivered using a similar electroporation protocol, six 100 µs pulses at 1500 V/cm.
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The three treatment protocol using the 1300 V/cm pulses also
increased the survival of mice that were given the vector control plasmid when compared to the two treatment protocol
using the 1500 V/cm pulses.
Delivery of phIL-15 Using EP Confers Resistance
to Challenge
Mice with tumors that completely regressed with long-term,
tumor-free survival were challenged by subcutaneous injection on the opposite flank of 50 µl B16.F10 melanoma cells
(0.5 3 106 cells). No additional treatments with phIL-15
or EP were administered. The mice were monitored for an
additional 50 days and tumor growth, if any was quantified.
The outcome of the challenge was represented as percentage
overall survival in Table I. Mice were called “resistant” if
they remained tumor free for the duration and “non-resistant”
if tumors grew at the secondary inoculation site. Of the mice
given phIL-15 delivered with 1300 V/cm, 100 µs pulses 5
out of 11 (45% of the original n) were resistant compared to
the control plasmid group in which 3 out of the 6 challenged
(21% of the original n) were resistant. The mice that received
phIL-15 using 500 V/cm, 20 ms pulses had 5 out of 7 mice
challenged (42% of the original n) were resistant to challenge
compared to 3 out of 9 (23% of the original n) being resistant
in the control plasmid group using the same EP condition.
This is a noteworthy observation, however the underlying
molecular mechanism of how delivery of control plasmid
leads to long-term survival and resistance to challenge in a
small percentage of animals is unclear at this time. These
results suggest that EP plays a large role in the tumor regression and resistance to challenge that were observed. They
also imply the generation of a memory immune response by
the animals to melanoma tumor antigens resulting from the
treatment of the initial subcutaneous tumor on the left flank.
Table I
Delivery of phIL-15 by electroporation results in long-term survival and
resistance to challenge. Mice that remained tumor free after the primary
inoculation of B16.F10 melanoma cells and delivery of pDNA using electroporation were challenged on the opposite flank with a subcutaneous injection of B16.F10 melanoma cells. They were monitored for an additional 50
days. Data represents animals that were tumor free 50 days post challenge.
Challenge
Total animals
Overall
(n)
Day 0 (n) Day 50 (n) survival (%)
phIL-15 injection
pVAX111300 V/cm
phIL-1511300 V/cm
pVAX11500 V/cm
phIL-151500 V/cm

12
14
11
13
12

0
6
11
91
7*

0
3
5
3
5

–
21
45
23
42

Of the 10 surviving animals in this group one was found dead on day 48.
*There was one mouse in this group that had a small tumor on day 51
that completely regressed by day 0 of challenge and was included in the
challenge.
1

This study has demonstrated the usefulness of using EP to
deliver phIL-15 as an anti-melanoma therapy. We have demonstrated that the therapeutic protein IL-15 can be expressed
in the tumor at levels sufficient to cause tumor regression and
generate a specific memory response that protects the animal
from developing tumors when challenged. We cannot rule
out that the delivery of the empty vector using EP may play a
role in the overall anti-tumor effect. However, it is clear from
these data that the delivery of IL-15 expressing plasmid by
EP results in a higher percentage of animals resistant to challenge. Additional studies need to be carried out to enhance the
stability of theIL-15 protein once it is produced to improve
the efficacy of the therapy. Another plasmid backbone could
be used in future experiments to express the therapeutic gene
in order to further study the effect of delivering non-coding
DNA by electroporation.
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